SEC Filing Coverage: Radius Health, Inc: Mpm Bioventures Iii-Qp L.P. Opened Big New Position

SEC Filing Coverage: Radius Health, Inc: Mpm Bioventures Iii Qp L.P. Opened Big New Position

The New Mpm Bioventures Iii-Qp L.P. Holding in Radius Health, Inc

Mpm Bioventures Iii-Qp L.P. filed with the SEC SC 13D/A form for Radius Health, Inc. The form can be accessed here: 000119312516729055. As reported in Mpm Bioventures Iii-Qp L.P.’s form, the filler as of late owns 9.5% or 4,111,022 shares of the Health Care–company.

Radius Health, Inc stake is a new one for the and it was filed because of activity on September27, 2016. We feel this shows Mpm Bioventures Iii-Qp L.P.’s positive view for the stock.

Reasons Why Mpm Bioventures Iii-Qp L.P. Bought – Radius Health, Inc Stock

“Item 4. Purpose of Transaction” of the Original Schedule 13D ishereby amended by adding the following at the end thereof:

Effective September27, 2016, the reporting persons distributed an aggregate of 1,943,751shares of the Issuer’s Common Stock to their respective limited partners and members on a pro rata basis for no additional consideration, as follows:

Reporting Person

Sharesof
CommonStockDistributed

BV III QP

1,023,819

BV III

68,835

BV III PF

30,911

BV III KG

86,522

AM LLC

19,815

MPM NVS

713,849

Radius Health, Inc Institutional Sentiment

Latest Security and Exchange filings show 118 investors own Radius Health, Inc. The institutional ownership in Q3 2015 is high, at 77.75% of the outstanding shares. This is increased by 3898009 the total institutional shares. 33494291 were the shares owned by these institutional investors. In total 25 funds opened new Radius Health, Inc stakes, 68 increased stakes. There were 21 that closed positions and 23 reduced them.

4 managers had the stock in their top Ten. Notable investors are: Mpm Asset Management Llc, Bb Biotech Ag, Brookside Capital Management Llc, Rock Springs Capital Management Lp..

Green Owl Capital Management Llc is an institutional investor bullish on Radius Health, Inc, owning 30000 shares as of Q3 2015 for 1.61% of its portfolio. Bain Capital Brookside Capital Management Llc owns 2018971 shares or 4.17% of its portfolio. V8 Bb Biotech Ag have 9.39% of their stock portfolio for 4272140 shares. Further, Rock Springs Capital Management Lp reported stake worth 3.15% of its US stock portfolio. The MA Mpm Asset Management Llc owns 5831253 shares. Radius Health, Inc is 62.17% of the manager’s US portfolio.

Business Profile

Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment increased to 1.32 in 2016 Q2. Its up 0.03, from 1.29 in 2016Q1. The ratio increased, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.

Citigroup reported 164,190 shares or 0.01% of all its holdings. Ing Groep Nv last reported 431,236 shares in the company. Alliancebernstein L P has 0.01% invested in the company for 430,600 shares. Salzhauer Michael accumulated 0.22% or 7,500 shares. The Pennsylvania-based Vanguard Grp Inc has invested 0.01% in Radius Health Inc (NASDAQ:RDUS). Quantitative Systematic Strategies Lc has invested 0.1% of its portfolio in Radius Health Inc (NASDAQ:RDUS). California Employees Retirement Sys, a California-based fund reported 78,200 shares. The Virginia-based Alexandria Cap Ltd Liability Corp has invested 0% in Radius Health Inc (NASDAQ:RDUS). State Bank Of America Corporation De holds 274,068 shares or 0% of its portfolio. Morgan Stanley has invested 0% of its portfolio in Radius Health Inc (NASDAQ:RDUS). The New York-based Blackrock has invested 0% in Radius Health Inc (NASDAQ:RDUS). Price T Rowe Associates Md last reported 588,571 shares in the company. Group One Trading Lp last reported 0.03% of its portfolio in the stock. Teachers Advsr has 50,400 shares for 0% of their US portfolio. Dimensional Fund Advsr L P has 11,514 shares for 0% of their US portfolio.

Analysts await Radius Health Inc (NASDAQ:RDUS) to report earnings on November, 3. They expect $-1.04 EPS, down 52.94% or $0.36 from last year’s $-0.68 per share. After $-1.01 actual EPS reported by Radius Health Inc for the previous quarter, Wall Street now forecasts 2.97% negative EPS growth.

About 373,155 shares traded hands. Radius Health Inc (NASDAQ:RDUS) has risen 84.61% since February 29, 2016 and is uptrending. It has outperformed by 72.39% the S&P500.

Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The company has a market cap of $2.23 billion. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. It currently has negative earnings. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women.

Radius Health Inc (NASDAQ:RDUS) Ratings Coverage

Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. $90 is the highest target while $37 is the lowest. The $68.88 average target is 30.48% above today’s ($52.79) stock price. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The company was maintained on Wednesday, September 21 by H.C. Wainwright. The rating was initiated by H.C. Wainwright with “Buy” on Monday, May 23. Jefferies downgraded the shares of RDUS in a report on Wednesday, February 24 to “Hold” rating. Deutsche Bank initiated Radius Health Inc (NASDAQ:RDUS) rating on Friday, August 14. Deutsche Bank has “Buy” rating and $90 price target. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, March 30 report. On Friday, October 2 the stock rating was initiated by JP Morgan with “Overweight”. Canaccord Genuity maintained Radius Health Inc (NASDAQ:RDUS) on Thursday, September 24 with “Buy” rating. As per Friday, May 6, the company rating was reinitiated by Cowen & Co.

More recent Radius Health Inc (NASDAQ:RDUS) news were published by: Fool.com which released: “Why Radius Health Inc. Dropped 45% in January” on February 08, 2016. Also Fool.com published the news titled: “Why Radius Health Inc. is Screaming Higher Today” on February 22, 2016. Philly.com‘s news article titled: “Radius Health eyes drug launch, expands in Wayne” with publication date: June 22, 2016 was also an interesting one.

According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”

RDUS Company Profile

Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment